Lung transplantation in Australia: barriers to translating new evidence into clinical practice

Greg Snell, Tom Kotsimbos and Trevor J Williams
Med J Aust 2006; 184 (9): . || doi: 10.5694/j.1326-5377.2006.tb00311.x
Published online: 1 May 2006

Evidence “beyond reasonable doubt” may never be achievable for low-volume drugs

The recent publication of a randomised controlled trial (RCT) of inhaled cyclosporin in the New England Journal of Medicine represents another milestone in the evolution of lung transplantation (LTx) as a standard therapy in the management of severe lung and pulmonary vascular diseases.1,2 RCTs have been few and far between in lung transplantation, and this is the first in such a high-profile general journal. However, the big question is: how will we integrate the study results into the clinical practice in Australia?

  • Greg Snell1,2
  • Tom Kotsimbos1,2
  • Trevor J Williams1,2

  • 1 The Alfred Hospital, Melbourne, VIC.
  • 2 Monash University, Melbourne, VIC.


Competing interests:

Greg Snell serves on the Transplant Advisory Board of Roche Pharmaceuticals. Both Greg Snell and Tom Kotsimbos have received speakers’ fees for delivering talks at Roche and Novartis Pharmaceutical meetings over the past 2 years, and travel assistance from Novartis Pharmaceuticals to attend the 2006 meeting of the International Society for Heart and Lung Transplantation.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.